A Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients With Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations
Endeavor Biomedicines, Inc.
Endeavor Biomedicines, Inc.
Roswell Park Cancer Institute
University of Washington
National Cancer Institute (NCI)
Fudan University
University Medical Center Groningen
University Medical Center Groningen
Huazhong University of Science and Technology
Dana-Farber Cancer Institute
Sumitomo Pharma America, Inc.
Pfizer
Eastern Cooperative Oncology Group
Peking Union Medical College Hospital
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Second Affiliated Hospital, School of Medicine, Zhejiang University
Institut Paoli-Calmettes
Vanquish Oncology, Inc.
Dana-Farber Cancer Institute
IRCCS San Raffaele
Pfizer
Dana-Farber Cancer Institute
Mauna Kea Technologies
National Institutes of Health Clinical Center (CC)
Peking Union Medical College Hospital
Dana-Farber Cancer Institute
University of Iowa
Federation Francophone de Cancerologie Digestive
Vanderbilt-Ingram Cancer Center
Medical College and Hospital Kolkata
National Cancer Institute (NCI)
Memorial Sloan Kettering Cancer Center
Novartis
National Cancer Institute (NCI)
H. Lee Moffitt Cancer Center and Research Institute
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)